Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.13
+1.9%
$4.42
$3.50
▼
$5.45
$632.33M0.842.94 million shs2.31 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$27.55
-1.8%
$31.54
$22.33
▼
$45.14
$2.16B1.041.07 million shs486,516 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$19.76
+1.9%
$21.28
$17.90
▼
$42.21
$2.37B0.151.21 million shs1.47 million shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$146.50
+1.5%
$143.15
$72.22
▼
$179.95
$2.14B-0.21262,219 shs91,421 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
+0.25%+6.02%-4.03%-18.67%-10.79%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-1.78%-8.52%+1.85%-32.76%+7.85%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-0.36%+1.09%-2.22%-32.04%-49.71%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-0.17%-14.44%+19.99%-3.74%+76.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.13
+1.9%
$4.42
$3.50
▼
$5.45
$632.33M0.842.94 million shs2.31 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$27.55
-1.8%
$31.54
$22.33
▼
$45.14
$2.16B1.041.07 million shs486,516 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$19.76
+1.9%
$21.28
$17.90
▼
$42.21
$2.37B0.151.21 million shs1.47 million shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$146.50
+1.5%
$143.15
$72.22
▼
$179.95
$2.14B-0.21262,219 shs91,421 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
+0.25%+6.02%-4.03%-18.67%-10.79%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-1.78%-8.52%+1.85%-32.76%+7.85%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-0.36%+1.09%-2.22%-32.04%-49.71%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-0.17%-14.44%+19.99%-3.74%+76.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.00
HoldN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.77
Moderate Buy$64.08132.64% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.83
Moderate Buy$49.82152.18% Upside
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.00
Buy$214.8646.67% Upside

Current Analyst Ratings Breakdown

Latest ABUS, NAMS, CLDX, and PVLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Initiated CoverageOutperform$228.00
11/11/2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
UpgradeHold (C) ➝ Hold (C+)
11/11/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Boost Price TargetOverweight$52.00 ➝ $61.00
11/9/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetBuy$60.00 ➝ $68.00
11/9/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetOverweight$57.00 ➝ $61.00
11/9/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Boost Price TargetBuy$232.00 ➝ $243.00
11/6/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Initiated CoverageStrong-Buy
11/6/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Boost Price TargetOutperform$210.00 ➝ $232.00
11/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Lower Price TargetBuy$48.00 ➝ $46.00
10/28/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Reiterated RatingBuy$240.00
10/20/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Reiterated RatingBuy
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$181.49M3.48N/AN/A$0.56 per share7.37
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,405.20N/AN/A$8.27 per share3.33
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M105.30N/AN/A$5.26 per share3.76
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M50.03N/AN/A$13.54 per share10.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$33.50M$1.133.65N/AN/A121.17%129.12%89.26%N/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.30N/AN/AN/AN/A-52.66%-47.58%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$1.69N/AN/AN/A-789.95%-31.39%-28.32%N/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$41.72M-$5.50N/AN/AN/AN/A-44.44%-36.75%N/A

Latest ABUS, NAMS, CLDX, and PVLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.0232$0.30+$0.3232$0.30$1.00 million$0.30 million
11/5/2026Q3 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.02-$0.96+$0.06-$0.96$0.72 million$0.40 million
11/5/2026Q3 2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$1.78-$1.70+$0.08-$1.70$0.02 millionN/A
11/4/2026Q3 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4718-$0.14+$0.3318-$0.14$8.82 million$19.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/A
1.40
1.40
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
10.97
10.97
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
11.76
11.76
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
16.01
16.01

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19.90%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
17.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19153.29 million122.79 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
19878.56 million74.48 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.93 million104.65 millionOptionable
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2914.62 million12.10 millionOptionable

Recent News About These Companies

FY2026 Earnings Forecast for PVLA Issued By HC Wainwright
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $232.00
Palvella (PVLA) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$4.12 +0.08 (+1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$4.11 -0.01 (-0.36%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$27.55 -0.49 (-1.76%)
Closing price 03:59 PM Eastern
Extended Trading
$27.55 +0.00 (+0.01%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$19.76 +0.37 (+1.88%)
Closing price 03:59 PM Eastern
Extended Trading
$19.75 0.00 (-0.03%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$146.50 +2.15 (+1.49%)
Closing price 03:59 PM Eastern
Extended Trading
$146.50 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.